Nordic Nanovector ASA: Share capital increase registered

 

Reference is made to the stock exchange notice dated 4th of March 2019 where Nordic Nanovector ASA (the "Company") announced that the board of directors had resolved to increase the share capital of the Company in connection with the former chairman of the Company Ludvik Sandnes' exercise of 27,121 RSUs.

Furthermore, an individual participant in the Company previous share option program, not being a primary insider, has exercised a total number of 200,000 options through exercise of a corresponding number of warrants. The options are exercised at a strike price of NOK 25.00 per share. Each warrant gives the right to receive one share in the Company.

Today the share capital increase pertaining to the RSUs and the options were duly registered in the Norwegian Register of Business Enterprises. Following registration, the share capital of the Company was increased by NOK 45,424.20 through issuance of 227,121 new shares, each with a nominal value of NOK 0.20, against payment of a total subscription price of NOK 5,005,424.20. Following the share capital increase the Company has a share capital of NOK 10,920,232 divided on 54,601,160 shares, each with a nominal value of NOK 0.20.

For further information, please contact:

Malene Brondberg, VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

About Nordic Nanovector  

Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.

Further information can be found at www.nordicnanovector.com.

This information is subject to a duty of disclosure pursuant to section 3.2 of the continuing obligations for listed companies.

 

Tags:

About Us

About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Subscribe